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A B S T R A C T
Background: The aim of the study is examine the impact of non-obstructive (< 50%stenosis) left main (LM)
disease on the natural history of coronary artery disease using serial coronary computed tomography angio-
graphy (CTA).
Methods: CTAs from the PARADIGM (Progression of atherosclerotic plaque determined by computed tomo-
graphic angiography imaging) study, a prospective multinational registry of patients who underwent serial CTA
at a ≥2 year interval were analyzed. Those without evidence of CAD on their baseline scan were excluded, as
were those with obstructive left main disease. Coronary artery vessels and their branches underwent quantiﬁ-
cation of: plaque volume and composition; diameter stenosis; presence of high-risk plaque.
Results: Of 944 (62 ± 9 years, 60% male) who had evidence of CAD at baseline, 444 (47%) had LM disease.
Those with LM disease had a higher baseline plaque volume (194.8 ± 221mm3 versus 72.9 ± 84.3mm3,
p < 0.001) and a higher prevalence of high-risk plaque (17.5% versus 13%, p < 0.001) than those without LM
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disease. On multivariable general linear model, patients with LM disease had greater annual rates of progression
of total (26.5 ± 31.4mm3/yr versus 14.9 ± 20.1mm3/yr, p < 0.001) and calciﬁed plaque volume
(17 ± 24mm3/yr versus 7 ± 11mm3/yr, p < 0.001), with no diﬀerence in ﬁbrous, ﬁbrofatty or necrotic core
plaque components.
Conclusion: The presence of non-obstructive LM disease is associated with greater rates of plaque progression
and a higher prevalence of high-risk plaque throughout the entire coronary artery tree compared to CAD without
LM involvement. Our data suggests that non-obstructive LM disease may be a marker for an aggressive phe-
notype of CAD that may beneﬁt from more intensive treatment strategies.
1. Introduction
Left main (LM) coronary artery disease (CAD) is associated with
high morbidity and mortality owing to the large mass of myocardium
subtended by this vessel.1–3 Due to this high-risk proﬁle both European
and American guidelines recommend coronary-artery bypass grafting
for those with obstructive LM disease.4,5 Non-obstructive LM disease is
also associated with signiﬁcantly increased risk of major adverse car-
diovascular events.6–8
Previous studies utilizing intravascular ultrasound (IVUS) have de-
monstrated that LM plaque volume and rate of progression is predictive
of major adverse coronary events.9 These studies have also shown that
longitudinal changes in LM plaque are associated with traditional risk
factors and receptive to targeted medical therapy of these.10,11 Whilst
providing insight into the nature of LM plaque and stenosis, these prior
studies have restricted their examination to either just the LM, or to
include the proximal left anterior descending (LAD) and/or left cir-
cumﬂex (LCx) vessels, and did not contain a control group of those
without LM disease.
While LM plaque rupture has an extremely poor prognosis, non-fatal
myocardial infarctions (MI) is also more common in LM disease un-
related to LM plaque rupture.6 This greater cardiovascular risk asso-
ciated with LM disease is independent of baseline plaque burden sug-
gesting that this cannot be the only factor determining downstream
risk.6 The longitudinal impact of the presence of LM disease on plaque
volume and progression rates in the context of the entirety of the cor-
onary artery circulation is currently unknown.
The purpose of the current study is to determine the long-term ef-
fects of LM disease on coronary atherosclerosis, using quantitative
metrics in patients who underwent serial coronary computer tomo-
graphic angiography (CTA). We hypothesize that the presence of LM
disease will be associated with more severe and extensive CAD at
baseline, a greater prevalence of high-risk plaque (HRP), and ac-
celerated plaque progression.
2. Methods
2.1. Study design
The current study is a substudy of the PARADIGM (Progression of
atherosclerotic plaque determined by computed tomographic angio-
graphy imaging) study. The design of the study has been described in
detail previously,12 but in brief it is a prospective international multi-
site observational registry in which clinical, procedural, and follow-up
data was collected on patients undergoing clinically indicated serial
CTA. The study protocol was approved by the institutional review
boards at all participating sites.
2.2. Study population
2252 patients at 13 sites in 7 countries were enrolled between 2003
and 2015. Those enrolled were consecutive patients with suspected or
known CAD undergoing serial CTA at an inter-scan interval of ≥2
years. Inclusion and exclusion criteria of the PARADIGM study have
been described in detail before.12 As the current study was to examine
the eﬀects of non-obstructive LM disease on progression of CAD those in
whom coronary revascularization occurred prior to follow-up CTA were
excluded from the study as were those with ≥50% stenosis within the
LM on baseline CTA. Those without CAD at baseline were also excluded
from the study so that the minimal segmental involvement score in both
groups was 1.
2.3. Coronary computed tomography angiography
All CTAs were performed in accordance with Society of
Cardiovascular Computed Tomography guidelines.13,14 All datasets
underwent blinded analysis at a single core laboratory. Coronary
atherosclerosis evaluation by CTA was performed on multiplanar and
cross-sectional images by Level III-experienced readers masked to
clinical results using semi-automated plaque analysis software (QAn-
gioCT Research Edition v2·1·9·1; Medis Medical Imaging Systems,
Leiden, the Netherlands) with manual correction.15
Brieﬂy, segments with a diameter ≥2mm were evaluated using a
modiﬁed 17-segment American Heart Association model for coronary
segment classiﬁcation.16 For longitudinal comparisons of CTAs, cor-
onary segments and lesions were co-registered between baseline and
follow-up CTAs using anatomical landmarks such as distance from ostia
or branch vessel takeoﬀs. Coronary segments not interpretable due to
motion artifact were excluded from the analysis.
Quantitative atherosclerosis analysis of all coronary vessels≥2mm
was performed at 1-mm cross-sectional intervals. Plaque volume (PV)
and vessel volume (PV) of all coronary segments were obtained at
baseline and follow-up CTAs, and then summated to generate total PV
and VV on a per-patient and per vessel level. Change in plaque volume
was calculated as annualized rate to account for the variability in time
between baseline and follow-up CTA between participants.
Compositional analysis was performed of all atherosclerotic pla-
ques, using Hounsﬁeld units (HU) cutoﬀ values of: −30 to 30 HU for
necrotic core; 30 to 130HU for ﬁbro-fatty plaque; 131 to 350HU for
ﬁbrous plaque; and ≥350HU for calciﬁed plaque. These thresholds
were determined based on prior validation studies compared against
intravascular ultrasound.17,18
We evaluated atherosclerotic plaque features previously reported as
being associated with incident major adverse cardiovascular events and
ischemia, and which have been termed high-risk plaques (HRP).19,20
HRP were deﬁned as coronary lesions with ≥2 of the following fea-
tures: positive remodeling (PR), low-attenuation plaque (LAP), napkin
ring sign (NRS) or spotty calciﬁcation (SC).21 LAP, previously corre-
lated to necrotic core, was deﬁned as any plaque containing≥1 voxels
with ≤30 HU.18,19 SC was deﬁned as presence of calciﬁcation< 3mm
in any direction within a plaque.20,22 PR was considered present when
the maximal lesion vessel area divided by a reference cross sectional
area 5-mm proximal to the beginning of the lesion was ≥1.1. If a
coronary lesion was present at the 5-mm cross-sectional mark, the re-
ference cross sectional area was the 1-mm cross-section closest to this
point without any atherosclerosis.
2.4. Study endpoints
The primary endpoint of the study was the diﬀerence in annualized
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per-segment change in PV between CTA-1 and CTA-2 between patients
with non-obstructive LM disease versus those with normal LM.
Secondary endpoints included annualized change in PV by composition,
prevalence of obstructive lesions and HRP at CTA-2.
2.5. Statistical analysis
Continuous variables are expressed as means ± standard deviation
(SD), and categorical variables are presented as absolute counts and
percentages. Between group diﬀerences were analyzed using the chi-
square test or Fisher's exact test for categorical variables, as appro-
priate, and those between continuous variables using Student's t-test.
Changes between CTA-1 and CTA-2 in categorical variables were ana-
lyzed using McNemar's test, and those between continuous variables
using a paired Student's t-test. For comparison of total plaque volume at
baseline, a general linear model (GLM) was performed using plaque
volume as the dependent variable, LM status as the ﬁxed factor, and
age, sex, hypertension, diabetes mellitus (DM), smoking history, body
mass index (BMI), and statin therapy as covariates. For comparison of
per patient annualized plaque progression rates, A general linear model
(GLM) was performed using plaque progression rate as the dependent
variable, LM status as the ﬁxed factor, and age, sex, hypertension,
diabetes mellitus (DM), smoking history, body mass index (BMI), and
statin therapy as covariates. A second GLM was performed using all the
variables from the ﬁrst model, with the addition of the baseline plaque
volume as an additional covariate, with the component plaque volume
of interest used as the baseline plaque volume. For example, when ﬁ-
brous plaque volume rate of progression was the independent variable
of interest, the model would include the baseline ﬁbrous plaque volume
as a covariate. A p value < 0·05 was considered to indicate a statisti-
cally signiﬁcant diﬀerence. All analyses were performed with SPSS
(version 22, IBM SPSS, NY).
2.6. Role of the funding source
This study was supported by grants from the Dalio Foundation,
Michael Wolk Foundation and the Leading Foreign Research Institute
Recruitment Program through the National Research Foundation of
Korea funded by the Ministry of Science, ICT and Future Planning
(Grant No. 2012027176). The funders of the study had no role in study
design, data collection, data analysis, data interpretation, or writing of
the report.
3. Results
3.1. Study population
Of the 2252 enrolled in the PARADIGM registry, 944 (60% male,
61.6 ± 9.0 years old) were included in the ﬁnal analysis (See
CONSORT diagram – Fig. 1). Of these, 500 (62% male, 62.7 ± 8.8
years old) had evidence of non-obstructive LM disease while 444 had
CAD without evidence of LM disease (57% male, 60.4 ± 9.2 years
old). Those with LM disease were older (p < 0.001), more likely to
have history of hypertension (LM+ve = 298 (60%) vs. LM−ve = 232
(52%), p = 0.02) or cerebrovascular accident (LM +ve = 35 (7%) vs.
LM −ve = 15 (3%), p = 0.006), and to have presented with typical
angina at baseline (LM +ve = 23 (5%) vs. LM −ve = 10 (2%),
p = 0.02). The populations were otherwise matched for baseline
characteristics (see Table 1).
3.2. Subject based plaque analysis
At baseline those with LM disease had a higher total plaque volume
(LM +ve = 194.8 ± 221 vs. LM −ve = 72.9 ± 84.3 mm3,
p < 0.001), with higher volumes of all constituent plaque types (cal-
ciﬁed, ﬁbrous, ﬁbrous fatty and necrotic, p < 0.001 for all.) These
diﬀerences persisted after correcting for baseline age, sex, hyperten-
sion, DM, BMI, smoking, and statin therapy (p < 0.001 for all - see
Table 2). At follow-up those with LM disease had a greater annualized
plaque progression rate for total plaque volume (LM +ve = 26.5 ±
31.4 vs. LM −ve = 14.9 ± 20.1 mm3/yr, p < 0.001). This was
driven by a greater annualized plaque progression rate for calciﬁed
plaque volume (LM +ve = 17.4 ± 24.0 vs. LM −ve = 7.2 ±
10.7 mm3/yr, p < 0.001), but with no diﬀerence in rate of progression
of ﬁbrous, ﬁbrous fatty or necrotic core components (p > 0.1 for all).
These diﬀerences persisted after correcting for baseline age, sex, hy-
pertension, DM, BMI, smoking, and statin therapy (p < 0.001) and
after further correcting for these factors in addition to baseline plaque
volume (p= 0.002).
3.3. Segmental analysis
These observations of more rapid progression of total plaque vo-
lume and calciﬁed plaque volume were observed at a segmental level.
Irrespective of vascular territory, there was more rapid calciﬁed plaque
Fig. 1. CONSORT ﬂow diagram of the PARADIGM study.
*n add up to more than 1308 as participants can be excluded for more than one reason.
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progression in those with LM CAD proximal LAD, proximal LCx, and the
proximal right coronary artery (RCA) (p < 0.005 for all - see Table 3
and Fig. 2). Similar observations were also present at a per lesion level
with greater total plaque progression (LM+ve = 6.46 ± 12.18 vs. LM
−ve = 4.75 ± 10.24 mm3/yr, p < 0.001), and calciﬁed plaque
progression (LM +ve = 4.64 ± 8.36 vs. LM −ve = 2.72 ±
4.51 mm3/yr, p < 0.001) in those with LM disease compared to those
without (See Table 4).
3.4. Lesion based analysis
Lesions present in those with LM disease were associated with a
greater average degree of stenosis (LM +ve = 19.6 ± 13.2 vs. LM
−ve = 16.2 ± 10.9%, p < 0.001) and more likely to be obstructive
(greater than 50% severity) (LM +ve = 39 (2.3%) vs. LM −ve = 9
Table 1
Baseline patient characteristics in the total population and by LM disease status.
Total LM −ve LM +ve p-value
N 944 444 500
Age (years) 61.6 ± 9.0 60.4 ± 9.2 62.7 ± 8.8 <0.001
Sex (male) 563 (60%) 255 (57%) 308 (62%) 0.19
BMI 25.4 ± 3.3 25.4 ± 3.4 25.5 ± 3.3 0.64
SBP 130 ± 17 130 ± 17 131 ± 17 0.26
DBP 78 ± 11 79 ± 11 78 ± 11 0.15
DM 221 (23%) 108 (24%) 113 (23%) 0.58
Hypertension 530 (56%) 232 (52%) 298 (60%) 0.02
Hyperlipidaemia 383 (41%) 173 (39%) 210 (42%) 0.29
Smoking Hx:
Current 191 (20%) 96 (22%) 95 (19%) 0.35
Previous 187 (20%) 87 (20%) 100 (20%) 0.82
Never 510 (54%) 241 (54%) 269 (54%) 0.81
FHx CVD 268 (28%) 129 (29%) 139 (28%) 0.67
CAD 18 (2%) 9 (2%) 9 (2%) 0.80
CVA 50 (5%) 15 (3%) 35 (7%) 0.006
PAD 7 (0.7%) 2 (0.4%) 5 (1%) 0.29
HbA1c 6.37 ± 1.13 6.37 ± 1.18 6.38 ± 1.08 0.94
TC 188 ± 39 188 ± 37 189 ± 40 0.86
HDL 51 ± 14 51 ± 14 51 ± 14 0.86
TG 145 ± 87 145 ± 90 145 ± 85 0.99
LDL 114 ± 34 115 ± 34 114 ± 34 0.73
CRP 1.63 ± 4.75 1.33 ± 2.26 1.90 ± 6.19 0.29
Medications
Aspirin 395 (43%) 175 (40%) 220 (45%) 0.14
Beta-blocker 256 (28%) 120 (28%) 136 (28%) 0.94
Calcium Channel
blocker
227 (25%) 112 (26%) 115 (49%) 0.41
Diuretic 92 (10%) 43 (10%) 49 (10%) 0.96
Renin-angiotensin
System inhibitor
294 (32%) 142 (33%) 152 (31%) 0.58
Statin Tx
(baseline)
407 (46%) 179 (43%) 228 (48%) 0.12
Statin Tx
(follow-up)
533 (62%) 243 (58%) 290 (65%) 0.07
Chest pain:
Typical angina 33 (3%) 10 (2%) 23 (5%) 0.048
Atypical angina 662 (70%) 324 (73%) 338 (68%) 0.11
Non cardiac 93 (10%) 44 (10%) 49 (10%) 0.98
Interval between CT
scans
3.7 ± 1.5 3.8 ± 1.5 3.7 ± 1.5 0.70
BMI – Body mass index; CAD – coronary artery disease; CRP – C-reactive pro-
tein; CVA – cerebrovascular accident; CVD – cardiovascular disease; DBP –
Diastolic blood pressure; DM – Diabetes mellitus; FHx – Family history; HbA1c –
Hemoglobin A1c; HDL – High density lipoprotein; LDL – Low density lipopro-
tein; PAD – peripheral arterial disease; TC – total cholesterol; SBP – Systolic
blood pressure; TG – triglycerides.
Signiﬁcant is deﬁned as a p-value<0.05.
Table 2
Per patient CTA ﬁndings at baseline and follow-up by left main status.
Total LM −’ve LM +’ve Unadjusted Model 1 Model 2
F, p-value F, p-value F, p-value
Total PV at baseline (mm3)
Total PV, mm3 137.3 ± 179.9 72.9 ± 84.3 194.8 ± 221 116.2,< 0.001 87.9,< 0.001
Calciﬁed PV, mm3 49.4 ± 101.1 22.4 ± 41.9 73.4 ± 128.7 62.0,< 0.001 43.6,< 0.001
Fibrous PV, mm3 60.4 ± 80.0 32.4 ± 39.6 85.4 ± 97.0 112.6,< 0.001 87.8,< 0.001
Fibrous fatty PV, mm3 24.5 ± 38.0 15.9 ± 27.8 32.1 ± 43.8 43.9,< 0.001 36.0,< 0.001
Necrotic core PV, mm3 3.1 ± 7.5 2.3 ± 5.9 3.9 ± 8.6 11.4, 0.001 8.6, 0.003
Annualized change in total PV (mm3/yr)
Total PV, mm3 21.0 ± 27.3 14.9 ± 20.1 26.5 ± 31.4 43.1,< 0.001 32.5,< 0.001 9.5, 0.002
Calciﬁed PV, mm3 12.6 ± 19.6 7.2 ± 10.7 17.4 ± 24.0 65.9,< 0.001 51.4,< 0.001 16.2,<0.001
Fibrous PV, mm3 7.1 ± 15.8 6.3 ± 12.3 7.8 ± 18.3 112.6, 0.14 2.0, 0.16 2.78, 0.10
Fibrous fatty PV, mm3 1.2 ± 10.3 1.3 ± 8.9 1.1 ± 11.4 0.1, 0.77 0.001, 0.97 0.02, 0.88
Necrotic core PV, mm3 0.1 ± 2.4 0.06 ± 1.7 0.13 ± 2.8 0.2, 0.65 0.2, 0.64 1.8, 0.18
Model 1 – Accounts for baseline age, sex, hypertension, Diabetes, body mass index, smoking, and statin therapy.
Model 2 – Model 1, plus baseline constituent plaque volume.
LM=Left main; PV=Plaque volume.
Signiﬁcant is deﬁned as a p-value<0.05.
Table 3
Per segment annualized change (mm3/yr) within the proximal segments ac-
cording to the presence or absence of left main disease.
LM −’ve LM +’ve p-value
LM
Total PV, mm3/year 0.48 ± 2.4 2.10 ± 5.0 <0.001
Calciﬁed PV, mm3/year 0.16 ± 1.6 1.67 ± 3.4 <0.001
Fibrous PV, mm3/year 0.23 ± 1.0 0.60 ± 3.2 0.025
Fibrous fatty PV, mm3/year 0.08 ± 0.48 −0.11 ± 2.1 0.07
Necrotic core PV, mm3/year 0.01 ± 0.07 −0.04 ± 0.63 0.16
pLAD
Total PV, mm3/year 2.26 ± 6.1 2.23 ± 6.1 0.94
Calciﬁed PV, mm3/year 0.94 ± 2.0 1.84 ± 4.0 <0.001
Fibrous PV, mm3/year 1.07 ± 3.5 0.79 ± 4.1 0.28
Fibrous fatty PV, mm3/year 0.29 ± 3.5 −0.32 ± 3.4 0.009
Necrotic core PV, mm3/year 0.00 ± 0.79 −0.08 ± 0.96 0.17
pLCx
Total PV, mm3/year 0.65 ± 2.2 1.36 ± 3.9 0.001
Calciﬁed PV, mm3/year 0.45 ± 1.5 0.90 ± 2.8 0.003
Fibrous PV, mm3/year 0.22 ± 1.2 0.44 ± 2.1 0.06
Fibrous fatty PV, mm3/year −0.02 ± 0.6 0.01 ± 1.4 0.66
Necrotic core PV, mm3/year −0.00 ± 0.2 0.00 ± 0.2 0.73
pRCA
Total PV, mm3/year 2.17 ± 5.7 3.77 ± 9.0 0.002
Calciﬁed PV, mm3/year 0.97 ± 2.8 2.00 ± 5.3 <0.001
Fibrous PV, mm3/year 1.07 ± 3.8 1.49 ± 5.0 0.17
Fibrous fatty PV, mm3/year 0.13 ± 2.2 0.27 ± 3.7 0.51
Necrotic core PV, mm3/year 0.01 ± 0.6 0.01 ± 0.7 0.94
LM=Left main; pLAD=proximal left anterior descending; pLCx= proximal
left circumﬂex; pRCA=proximal right coronary artery; PV = Plaque volume.
Signiﬁcant is deﬁned as a p-value< 0.05.
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(0.8%), p < 0.001 – see Table 4). HRP made up a higher proportion of
plaques in those with left main disease (LM +ve = 300/1713 (17.5%)
vs. LM −ve = 142/1089 (13%), p = 0.001). This was driven by a
higher frequency of spotty calciﬁcation (LM +ve = 236/1713 (13.8%)
vs. LM −ve = 83/1089 (7.6%), p = 0.001), with no diﬀerence in the
frequency of positive remodeling, low attenuation plaque or the napkin
ring sign (p > 0.2 for all – see Table 4).
4. Discussion
In the current study we have shown that LM disease is associated
with a higher plaque volume, greater plaque rate progression, more
severe stenosis and a higher prevalence of HRP features.
The ﬁnding that LM disease is associated with a greater global
plaque burden within the coronary arterial tree is consistent with pre-
vious studies showing a high prevalence of single, double and triple
vessel CAD and a higher segment involvement score with LM dis-
ease.6,23,24 This is important as multiple studies have consistently de-
monstrated an increasing mortality with increasing burden of both
obstructive and non-obstructive plaque.25–27
Plaque progression has previously been demonstrated to be the
strongest imaging feature associated with later development of acute
coronary syndrome, with the presence of HRP providing additive
prognostic value.19 In the current study we observed both these risk
Fig. 2. Annualized change in total plaque volume within the proximal segments according to presence or absence of left main disease.
LM=Left main; pLAD=proximal left anterior descending; pLCx=proximal left circumﬂex; pRCA=proximal right coronary artery.
Table 4
Per lesion comparison of plaque characteristics between those with and without left main disease.
Lesions in LM +ve p-value between baseline vs∙
follow-up
Lesions in LM −ve p-value between baseline vs∙
follow-up
p-value between groups
(n= 1713) (n= 1089)
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Stenosis severity
Diameter stenosis
≥50%
39 (2.3%) 72 (4.2%) <0.001 9 (0.8%) 21 (1.9%) 0.02ˆ 0.001 < 0.001
Stenosis severity, % 19.6 ± 13.2 22.3 ± 13.8 <0.001 16.2 ± 10.9 19.6 ± 12.1 <0.001 <0.001 <0.001
High-risk plaque characteristics
High-risk plaque* 300 (17.5%) 336 (19.6%) 0.014 142 (13.0%) 179 (16.4%) 0.001 0.001 0.004
Positive remodeling 1187 (69.3%) 1301 (76.0) <0.001 774 (71.1%) 847 (77.8%) <0.001 0.28 0.64
Low attenuation plaque 202 (11.8%) 194 (11.3%) 0.46 112 (10.3%) 109 (10.0%) 0.80 0.30 0.26
Spotty calciﬁcation 236 (13.8%) 259 (15.1%) 0.06 83 (7.6%) 126 (11.6%) <0.001 0.001 < 0.001
Napkin ring sign 8 (0.5%) 5 (0.3%) 1ˆ 4 (0.4%) 3 (0.3%) 1ˆ 1 0.75
Annualized change in PV
Total PV, mm3/yr 6.46 ± 12.18 4.75 ± 10.24 < 0.001
Calciﬁed PV, mm3/yr 4.64 ± 8.36 2.72 ± 4.51 < 0.001
Fibrous PV, mm3/yr 1.70 ± 7.67 1.75 ± 5.97 0.83
Fibrous fatty PV, mm3/
yr
0.11 ± 4.81 0.31 ± 5.15 0.32
Necrotic core PV, mm3/
yr
0.02 ± 1.30 −0.02 ± 0.95 0.39
Data are n (%) or mean (SD). CTA= coronary computed tomography angiography; DS=diameter stenosis; PV= plaque volume.
*High-risk plaque is deﬁned as lesions with ≥2 of low attenuation plaque, spotty calcium, napkin ring sign, or positive remodeling. ˆMcNemar Exact p-value.
LM=Left main; PV = Plaque volume.
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factors with a higher rate of progression of plaque and a greater fre-
quency of HRP features in those with LM disease. The higher frequency
of HRP features was driven by a higher incidence of spotty calciﬁcation
in the LM group. This HRP feature is associated with unstable plaque
morphology, culprit lesions in acute coronary syndromes, and ac-
celerated plaque progression despite the use of medical therapy.28–31
The combination of a greater plaque volume and higher prevalence of
spotty calciﬁcation in patients with LM disease suggest a more ag-
gressive atherosclerosis process which may be driving LM disease rather
than a result of it. In support of this is that the greater rate of plaque
progression was present independent of coronary artery site, with
equally advanced rates of plaque progression occurring in the right
coronary artery as in the proximal LAD and LCx suggesting a systemic
rather than localized process. This is a useful observation as it provides
some insight into the results of the recent EXCEL (Evaluation of XIENCE
versus Coronary Artery Bypass Surgery for Eﬀectiveness of Left Main
Revascularization) and NOBLE (Nordic-Baltic-British left main re-
vascularisation) trials, where increased revascularization rates were
observed in patients undergoing LM percutaneous coronary interven-
tion compared with coronary artery bypass graft surgery.27,32 However,
in these studies it was not the LM itself needing repeat revasculariza-
tion, rather, it was revascularization of de novo lesions that drives this
signal.32 These results have also been borne out in substudy analysis of
several other studies comparing percutaneous coronary intervention
with coronary artery bypass surgery in those with LM disease.33–36
Thus, it may be that the presence of LM disease is a marker of a need for
more aggressive therapeutic intervention.
Both the PROSPECT (Providing Regional Observations to Study
Predictors of Events in the Coronary Tree) study using IVUS and a study
by Motoyama et al. using CTA have described plaque volume, HRP,
plaque progression and severe stenosis to be independent markers of an
increased risk of cardiovascular events.19,37 That all four of these
markers are more prevalent in patients with LM disease provides fur-
ther insights into the reported higher rates of cardiovascular mortality
in this cohort and a need for more aggressive risk factor modiﬁcation.
There are several limitations to the current analysis. Both the ﬁrst
and second CTA were performed for clinical indications. Thus, while all
participants who underwent revascularization were excluded, the cur-
rent observations cannot be considered a true representation of the
‘natural history’ of CAD. Instead, they are the natural history in the
presence of persistent symptomatology or ongoing clinical concern.
However, given that this is the population faced clinically, and of
particular challenge to clinicians, this is perhaps a more relevant nat-
ural history to daily practice. Secondly, the current study is an ob-
servational study without protocolled guidance on management
strategy. As such, it is entirely possible that management may diﬀer
between the two groups. While baseline therapy was available and
equal between the groups, downstream medications at follow-up were
not. However, given the presence of both LM disease and a higher
baseline plaque burden, one would expect that if either group were to
be the recipients of a more intensive treatment regime, it would be the
LM disease group. As statin use causes a reduction in total plaque vo-
lume, and a fall in the prevalence of HRP,38,39), this would cause a
resultant reduction in the magnitude of between group diﬀerences.
Finally, as the study focused on those with non-obstructive LM disease
it is possible that as the stenosis becomes more severe, local hemody-
namic eﬀects and ﬂow destabilization may occur resulting in a regional
pattern of plaque progression secondary to this over and above the
globalized pattern observed in the current study. Further work in this
ﬁeld for better understanding however is unlikely to occur due to the
morbidity and mortality implications of leaving severe LM stenosis
untreated in order to observe for these longitudinal eﬀects.
5. Conclusion
Those with non-obstructive LM disease have greater plaque burden,
greater rates of plaque progression and a higher prevalence of high-risk
plaque throughout the entire coronary artery tree. This suggests that
LM disease is a marker for an aggressive phenotype of CAD that may
beneﬁt from more intensive treatment strategies.
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